Johnson & Johnson Q1 sales rise 9.9%, raises 2026 outlook; net earnings fall 52.4%
Johnson & Johnson reported first-quarter 2026 reported sales of $24.1 billion, up 9.9%, and raised its full-year 2026 guidance, with estimated reported sales of $100.8 billion at the midpoint. Net earnings fell 52.4% to $5.2 billion, and the prior-year quarter included a large litigation-related gain, while adjusted EPS declined 2.5% to $2.70. The board also raised the quarterly dividend 3.1% to $1.34 per share.
Key points
- Reported sales rose 9.9% to $24.1 billion; U.S. sales rose 8.3% to $13.3 billion.
- Net earnings were $5.2 billion, or $2.14 per diluted share, versus $11.0 billion, or $4.54, a year earlier.
- Adjusted EPS was $2.70 versus $2.77; 2026 adjusted EPS guidance midpoint is $11.55, up from $11.53 in January.
- Quarterly dividend rises to $1.34 from $1.30; ex-dividend date is May 26, 2026, payable June 9, 2026.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.